Novozymes Biopharma
Castle Court 59 Castle Boulevard
Nottingham
NG7 1FD
United Kingdom
Tel: 44-0115-955-3355
Fax: 44-0115-955-1299
Website: http://www.novozymes.com/en
29 articles about Novozymes Biopharma
-
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
8/15/2018
VBI Vaccines Inc.
-
Novozymes Biopharma Enters License Agreement With EpiVax, Inc. To Advance Pioneering Treatment Of Autoimmune Diseases
12/23/2014
-
EpiVax, Inc. Enters License Agreement With Novozymes Biopharma To Advance Pioneering Treatment Of Autoimmune Diseases
12/22/2014
-
Novozymes Biopharma Enters Agreement With A Leading Vaccine Company To Conduct Research On A Novel Subunit Vaccine Complex Based On Albumin Fusion Technology
5/29/2014
-
Novozymes Biopharma To Offer Drug-Albumin Conjugation Platform In Collaboration With Thiologics
5/13/2014
-
Novozymes Biopharma Announces Collaboration With Janssen Research & Development To Evaluate Proprietary VELTISĀ® Half-Life Extension Technology
3/13/2014
-
Novozymes Biopharma Announces New Data Highlighting Potential For Monthly Drug Dosing
1/27/2014
-
Novozymes Biopharma Announces Collaboration With Almac Group in Drug Manufacture, Half Life Extension and Targeting Technologies
10/22/2013
-
Novozymes Biopharma's rAlbumin Approved in Japan as MAQUET Expands Into New Market
2/28/2013
-
EpiVax, Inc.-Novozymes Biopharma Tregitope-Albumin Fusion Moves "Paradigm-Shifting" Treatment for Diabetes Closer to Clinical Trials
2/12/2013
-
Novozymes Biopharma Aligns Recombinant Human Albumin Portfolio With New Brand Name
1/29/2013
-
Novozymes Biopharma Opens Hyaluronic Acid Plant in Tianjin
5/17/2012
-
Novozymes Biopharma' Ralbumin Supports Faster Time to Market for Neomend Adhesion Barrier Sealant
5/2/2012
-
Repligen Corporation Completes Acquisition of Novozymes Biopharma Sweden AB
12/20/2011
-
Novozymes Biopharma Expands Collaboration with Upperton Limited to Offer Customers New Albumin Conjugation Solution
12/8/2011
-
Novozymes Biopharma Supplies R-Tech Ueno with Albucult for Use in Unique Dry Eye Therapy
11/15/2011
-
Repligen Corporation Buys Novozymes Biopharma Unit for $22.7 Million
10/28/2011
-
Novozymes Biopharma to Present Latest Advances in Cell Culture Technology at ESACT
4/12/2011
-
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
3/21/2011
-
Novozymes Biopharma Presents Research on Recombinant Human Albumin at 2011 PepTalk Conference
1/6/2011